T and NK cell mediated immunotherapy in Ewing's sarcoma (P03.040 amended version of December 2006)

Not yet recruiting

• Conditions: bone tumors; 10040778

• Registration Number: NL-OMON31114
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 25

Inclusion Criteria

All newly diagnosed Ewing's sarcoma patients in the LUMC.

Exclusion Criteria

Lack of written informed consent

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>This preclinical study will provide insight in the molecular mechanisms<br /><br>involved in directional migration, recognition and elimination by T/NK cells of<br /><br>ES. In addition, we will identify potential immune evasion strategies in ES.<br /><br>Potential differences between autologous and allogeneic effector cells will be<br /><br>identified.<br /><br>Together, this study will provide evidence for the implementation of NK and/or<br /><br>T cell-mediated immunotherapy strategies in future clinical studies. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable</p><br>